Hep G2 Xenograft Model Service for Liver Cancer

The Hep G2 cell line serves as a highly robust and well-characterized in vivo platform for investigating the molecular pathways and therapeutic vulnerabilities of hepatocellular carcinoma (HCC). As a premier pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision Hep G2 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your liver cancer drug discovery and development pipeline.

Overview of Hep G2 Xenograft Model for Liver Cancer

The Hep G2 xenograft model is an established in vivo translational system widely utilized in oncology research for the study of hepatocellular carcinoma. By transplanting human Hep G2 cells into immunodeficient rodent hosts, this model effectively reproduces the solid tumor growth characteristics, histopathological architecture, and proliferative patterns typical of human primary liver malignancies.

Biologically, the Hep G2 model is highly valued for its consistent tumor formation and its status as a well-differentiated, epithelial-like cell line, which provides a relevant genetic background for studying hepatocyte-derived carcinomas. This model preserves key molecular features of HCC, including high metabolic activity and responsiveness to a wide array of experimental therapeutics, such as tyrosine kinase inhibitors and novel cytotoxic agents. Consequently, the Hep G2 model is extensively deployed in pre-clinical screening programs to assess the anti-tumor potency of novel compounds in a physiologically relevant in vivo setting.

Fig 1. Effects of KLX on HepG2 cell proliferation. (Wang, Z., et al., 2025)

Cell Line Information: Hep G2

The Hep G2 cell line is derived from a human hepatoblastoma (often classified within the hepatocellular carcinoma research spectrum). These cells exhibit stable, polarized growth characteristics in vitro, making them a preferred choice for developing reproducible tumor models for cancer research.

Our Services

Workflow of Hep G2 Xenograft Model Construction

• Cell Culture & Quality Control: Human Hep G2 cells are expanded in vitro using certified nutrient media under optimized physiological conditions. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic integrity and purity.
• Host Selection & Preparation: Immunodeficient mice (e.g., BALB/c nude or NCG) are sourced from validated vendors and acclimatized to facility conditions to stabilize baseline biological metrics.
• Precision Inoculation: A calibrated suspension of high-viability Hep G2 cells is prepared, often supplemented with an extracellular matrix (e.g., Matrigel) to optimize take rates. Cells are inoculated in vivo via subcutaneous injection into the host flank to facilitate the development of a measurable, solid tumor.
• Longitudinal Monitoring: Tumor dimensions are measured systematically using digital calipers to monitor volume progression. Animal health, activity, and body weight are recorded periodically to document systemic tolerance and clinical status.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, animals are randomized into experimental cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 2. Hep G2 Xenograft Model Construction Workflow

Case Study - Hep G2 Xenograft Model Development

A pre-clinical validation study was conducted using the Hep G2 xenograft model to evaluate the therapeutic efficacy of a novel anti-HCC candidate. Following the successful subcutaneous inoculation of Hep G2 cells into immunodeficient mice, the host animals developed firm, rapidly growing solid tumors. The treatment group demonstrated a clear, statistically significant inhibition of tumor growth compared to the vehicle-treated control group, confirming the model's high sensitivity and predictive reliability for screening novel liver cancer interventions.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse solid tumor lineages, providing highly reproducible in vivo translational platforms for liver cancer research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your liver cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our Hep G2 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.